Genfit is a late-stage biopharmaceutical company specializing in the discovery and development of innovative therapeutic and diagnostic solutions for metabolic and liver-related diseases, addressing significant unmet medical needs. The company's research leverages its expertise in modulating gene expression through nuclear receptors, utilizing rational drug design to optimize drug candidates. With a strong foundation in scientific and clinical expertise, Genfit employs a translational, disease-driven approach and advanced bioinformatics capabilities to create a robust platform for drug discovery and development. Co-founded by Professor Bart Staels, a recognized expert in nuclear receptors, Genfit benefits from his leadership as chair of the Scientific Advisory Board, enhancing the company's commitment to innovation in the metabolic field. Through strategic alliances, acquisitions, and licensing agreements, Genfit seeks to fund the advancement of its products, which hinge on successful clinical development.
Esperion discovers and develops pharmaceutical products for the treatment of cardiovascular and metabolic diseases. Esperion intends to commercialize a novel class of drugs that focuses on a new treatment approach called "HDL Therapy," which is based on the Company's understanding of high-density lipoprotein, or HDL, function.
Liquidia Technologies
Post in 2024
Liquidia Technologies is a late-stage clinical biopharmaceutical company based in the United States, dedicated to developing and commercializing innovative therapeutics. Utilizing its proprietary PRINT technology, a particle engineering platform, Liquidia produces uniform drug particles aimed at enhancing the safety and efficacy of various therapies. The company is advancing two key product candidates: LIQ861, intended for the treatment of pulmonary arterial hypertension, and LIQ865, designed for managing local post-operative pain. Additionally, Liquidia collaborates with leading pharmaceutical firms to leverage its PRINT technology across multiple therapeutic areas, molecule types, and administration routes, addressing unmet patient needs, particularly in the realm of pulmonary hypertension.
TG Therapeutics
Post in 2024
TG Therapeutics, Inc. is a biopharmaceutical company based in New York that specializes in the development and commercialization of treatments for B-cell malignancies and autoimmune diseases. The company has a strong focus on creating therapies through its B-cell directed research and development platform. Its lead product, Ublituximab, a glycoengineered monoclonal antibody, is approved for treating relapsing forms of multiple sclerosis and is also being evaluated for non-Hodgkin lymphoma and chronic lymphocytic leukemia. Additionally, TG Therapeutics is advancing TG-1701, a selective Bruton’s tyrosine kinase (BTK) inhibitor, and TG-1801, a bispecific antibody targeting CD47 and CD19. The company is engaged in various preclinical programs and has established strategic partnerships with several biotechnology firms to enhance its research capabilities.
OPKO Health, Inc. is a multinational healthcare company that operates in the diagnostics and pharmaceuticals sectors. Its Diagnostics segment includes BioReference Laboratories, which provides a range of laboratory testing services, including core genetic testing and the 4Kscore prostate cancer test. The Pharmaceuticals segment offers several treatments, including Rayaldee for secondary hyperparathyroidism, and is developing drugs such as OPK88004, a selective androgen receptor modulator, and OPK88003 for type 2 diabetes and obesity. Additionally, OPKO is advancing hGH-CTP, a once-weekly human growth hormone injection, and has various products targeting chemotherapy-induced nausea, hemophilia, and other medical conditions. The company also engages in the development and commercialization of specialty active pharmaceutical ingredients and a range of pharmaceutical, nutraceutical, and veterinary products. With operations spanning countries such as Ireland, Chile, Spain, and Mexico, OPKO Health focuses on leveraging its proprietary technologies and expertise to grow in key medical markets. Headquartered in Miami, Florida, OPKO Health was incorporated in 1991.
Zevra Therapeutics
Post in 2024
Zevra Therapeutics is a development-stage biopharmaceutical company focused on creating new therapies for pain, ADHD, and other central nervous system (CNS) diseases, particularly in the realm of rare diseases. The company is dedicated to developing safer, abuse-resistant opioid pain relievers and employs a proprietary Ligand Activated Therapy (LAT) approach to drug discovery and development. This innovative platform allows Zevra to enhance existing medications and streamline the development process while preserving strong intellectual property rights. By integrating scientific research with patient needs and data-driven strategies, Zevra Therapeutics aims to address the challenges of drug development, delivering transformational therapies for conditions with limited or no treatment options.
Liquidia Technologies
Post in 2024
Liquidia Technologies is a late-stage clinical biopharmaceutical company based in the United States, dedicated to developing and commercializing innovative therapeutics. Utilizing its proprietary PRINT technology, a particle engineering platform, Liquidia produces uniform drug particles aimed at enhancing the safety and efficacy of various therapies. The company is advancing two key product candidates: LIQ861, intended for the treatment of pulmonary arterial hypertension, and LIQ865, designed for managing local post-operative pain. Additionally, Liquidia collaborates with leading pharmaceutical firms to leverage its PRINT technology across multiple therapeutic areas, molecule types, and administration routes, addressing unmet patient needs, particularly in the realm of pulmonary hypertension.
Cara Therapeutics
Post in 2023
Cara Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Stamford, Connecticut, specializing in the development and commercialization of innovative therapeutics for pain and pruritus. The company primarily focuses on its lead product candidate, CR845 (difelikefalin), which is designed to selectively target kappa opioid receptors and is currently undergoing Phase III clinical trials for treating moderate-to-severe chronic kidney disease-associated pruritus in patients undergoing hemodialysis. Cara is also advancing Oral KORSUVA, which has completed Phase II trials for pruritus in chronic kidney disease and is in trials for pruritus associated with chronic liver disease and atopic dermatitis. Furthermore, the company is developing CR845/difelikefalin Injection for acute postoperative pain, having completed Phase II/III trials. Cara Therapeutics collaborates with Maruishi Pharmaceutical Co., Ltd. and Chong Kun Dang Pharmaceutical Corporation for the development and commercialization of its product candidates in Japan and South Korea, respectively. Founded in 2004, Cara Therapeutics aims to leverage its proprietary drug screening technology to create a pipeline of first-in-class therapeutics.
Liquidia Technologies
Post in 2023
Liquidia Technologies is a late-stage clinical biopharmaceutical company based in the United States, dedicated to developing and commercializing innovative therapeutics. Utilizing its proprietary PRINT technology, a particle engineering platform, Liquidia produces uniform drug particles aimed at enhancing the safety and efficacy of various therapies. The company is advancing two key product candidates: LIQ861, intended for the treatment of pulmonary arterial hypertension, and LIQ865, designed for managing local post-operative pain. Additionally, Liquidia collaborates with leading pharmaceutical firms to leverage its PRINT technology across multiple therapeutic areas, molecule types, and administration routes, addressing unmet patient needs, particularly in the realm of pulmonary hypertension.
Clearside Biomedical
Post in 2022
Clearside Biomedical, Inc. is a biopharmaceutical company focused on developing treatments for serious eye diseases with the aim of restoring and preserving vision. Founded in 2011 and headquartered in Alpharetta, Georgia, the company specializes in a proprietary ocular microinjection platform that allows for targeted delivery of therapeutic products to specific compartments of the eye. This innovative approach includes the use of the SCS Microinjector for administering therapies directly into the suprachoroidal space, enabling a non-surgical, repeatable procedure. Among its product pipeline, Clearside is developing XIPERE, a triamcinolone acetonide injectable suspension for macular edema, and CLS-AX, an axitinib for suprachoroidal injection. The company is dedicated to advancing pharmacological therapies for sight-threatening conditions by ensuring precise and effective treatment delivery.
Ardelyx, Inc. is a biopharmaceutical company specializing in the development and commercialization of innovative oral therapeutics for cardiorenal diseases. Founded in 2007 and headquartered in Fremont, California, the company focuses on addressing significant unmet medical needs through first-in-class medicines. Its lead product candidate, tenapanor, has completed Phase 3 clinical trials for treating irritable bowel syndrome with constipation and hyperphosphatemia in end-stage renal disease patients on dialysis. Additionally, Ardelyx is advancing RDX013, a small molecule potassium secretagogue targeting hyperkalemia, and has other candidates in its pipeline, including RDX002 and RDX009, which are in preclinical development for chronic kidney disease and type 2 diabetes, respectively. Ardelyx employs a proprietary drug discovery platform aimed at creating non-systemic products that target specific transporters and receptors to minimize side effects associated with systemic exposure.
Rhythm Pharmaceuticals
Post in 2022
Rhythm Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to the development and commercialization of therapeutics for rare genetic disorders, particularly those that lead to life-threatening metabolic conditions. The company’s primary product candidate, setmelanotide, is a first-in-class melanocortin-4 receptor agonist currently undergoing Phase III clinical trials for the treatment of obesity related to pro-opiomelanocortin (POMC) and leptin receptor deficiencies, as well as Bardet-Biedl and Alström syndromes. Additionally, it is in Phase II trials for various other genetic obesity disorders. Rhythm Pharmaceuticals is also advancing RM-853, an orally available ghrelin o-acyltransferase inhibitor in preclinical development aimed at addressing Prader-Willi syndrome. Founded in 2008 and based in Boston, Massachusetts, the company previously operated under the name Rhythm Metabolic, Inc. and rebranded in October 2015.
Spero Therapeutics
Post in 2021
Spero Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, dedicated to developing innovative treatments for multi-drug resistant (MDR) bacterial infections and rare diseases. Founded in 2013, the company is advancing several product candidates, including tebipenem pivoxil hydrobromide, an oral carbapenem-class antibiotic aimed at treating MDR gram-negative infections in adults. Additionally, Spero is developing SPR206, an intravenous agent for MDR gram-negative infections in hospital settings, and SPR720, an oral antibiotic targeting pulmonary non-tuberculous mycobacterial disease. The company collaborates with various partners, including Meiji Seika Pharma to support tebipenem HBr's development and the Bill & Melinda Gates Medical Research Institute for SPR720. Spero Therapeutics employs a focused approach to drug development, emphasizing novel mechanisms to address the urgent need for effective therapeutics against serious bacterial infections.
Portola Pharmaceuticals
Post in 2019
Portola Pharmaceuticals, Inc. is a biopharmaceutical company headquartered in South San Francisco, California, founded in 2003. It specializes in developing and commercializing innovative therapeutics primarily aimed at treating thrombosis, hematologic disorders, and inflammation. The company's lead product is Andexxa, an antidote for the anticoagulants rivaroxaban and apixaban. Additionally, Portola offers Bevyxxa, a once-daily oral Factor Xa inhibitor designed to prevent venous thromboembolism in adults with acute medical conditions. The firm is also developing several investigational products, including cerdulatinib, an oral dual inhibitor for hematologic cancers, and other compounds targeting chronic inflammatory diseases and cardiovascular conditions. Portola engages in collaborative agreements with various pharmaceutical companies to enhance its research and development efforts. As of July 2020, it operates as a subsidiary of Alexion Pharmaceuticals, Inc.
Coherus Biosciences
Post in 2019
Coherus Biosciences is a biopharmaceutical company that specializes in the development, manufacture, and commercialization of biologic therapeutics, with a strong emphasis on oncology and inflammatory diseases. The company is actively engaged in research and development, focusing on process science, analytical characterization, and protein production. Coherus's portfolio includes FDA-approved products such as UDENYCA, a biosimilar of Neulasta, and it plans to launch YUSIMRY, a biosimilar of Humira, in the United States. Additionally, the company is advancing a pipeline of biosimilar candidates across areas such as immunology and ophthalmology, as well as anti-tumor necrosis factor treatments. With a commitment to building an immuno-oncology franchise, Coherus aims to leverage its diversified portfolio to generate revenue and enhance patient access to biologic therapies.
TearScience
Series D in 2016
TearScience, Inc. is a medical device company based in Morrisville, North Carolina, focused on the identification, diagnosis, and treatment of Meibomian Gland Dysfunction (MGD), which is the primary cause of evaporative dry eye affecting over 100 million people globally. The company has developed innovative devices such as the LipiFlow Activator, which delivers automated therapeutic energies to meibomian glands while safeguarding the eye's delicate structures, and LipiScan, an imaging system that allows eye care professionals to assess gland health. MGD is often under-recognized and contributes significantly to dry eye symptoms such as irritation, dryness, and visual disturbances. By providing a comprehensive in-office system, TearScience enables eye care professionals to effectively address the root causes of evaporative dry eye, ultimately improving patient outcomes. The company, originally known as Kolis Scientific, Inc., was rebranded in 2005 and is now a subsidiary of Johnson & Johnson Surgical Vision, Inc.
Invuity
Private Equity Round in 2015
Invuity, Inc. is a medical technology company based in San Francisco, California, focused on developing and marketing advanced surgical devices in the United States and Asia. Utilizing its intelligent photonics technology platform, Invuity creates both single-use and reusable illuminated surgical devices that enhance visualization during surgical procedures. The company's product lineup includes various illuminated retractors and handheld illuminators designed for a range of specialties, such as breast, orthopedic, gynecological, and spinal surgeries. Notable offerings include the Eikon LT illuminated retractor system, Eiberg illuminated retractors, and the PhotonBlade and PhotonSaber series, which provide targeted illumination to improve surgical outcomes. Invuity sells its devices through direct sales representatives, independent agents, and directly to hospitals and surgeons, as well as to third-party medical device manufacturers. Previously known as Spotlight Surgical, Inc., Invuity was founded in 2004 and operates as a subsidiary of Stryker Corporation.
Helomics Corporation, established in 1995 and headquartered in Pittsburgh, Pennsylvania, is a personalized healthcare company specializing in cancer care. It develops and delivers a portfolio of products to aid physicians and patients in making informed clinical decisions. Helomics' core technology, the Precision Cellular Analytical Platform, collects and analyzes cell cycle and proliferation data over an extended period. Key products include ChemoFx, BioSpeciFx, GeneFx Colon, and GeneFx Lung, which help physicians select effective treatments and understand potential drug responses or prognosis. The company also offers tumor profiling services, contract research and development, and biorepository and banking services. Helomics operates as a contract research organization (CRO), providing oncology insights for six primary cancers and using artificial intelligence and its D-CHIP platform to create personalized oncology roadmaps. It serves the pharmaceutical, diagnostic, biotechnology, and research industries, aiming to improve patient outcomes through personalized treatments and diagnostics.
Cardiorentis
Series A in 2014
Cardiorentis AG is a biopharmaceutical company based in Zug, Switzerland, that focuses on developing drug therapies for acute heart failure and related cardiovascular diseases. Founded in 2010, the company is known for its lead product, ularitide, an intravenous infusion treatment aimed at addressing acute heart failure. Cardiorentis is conducting clinical studies, including the TRUE-AHF trial and the SIRIUS I and II studies, to evaluate the safety and efficacy of ularitide in patients with symptomatic and decompensated chronic heart failure. The company employs a disease-based technology platform that combines protein biology with the design of small molecule compounds and peptides. By fostering strong partnerships with academic researchers and clinicians, Cardiorentis aims to advance scientific knowledge and improve patient outcomes in the realm of cardiovascular care.
AcuFocus
Venture Round in 2014
AcuFocus, Inc. is an ophthalmic medical device company based in Irvine, California, specializing in small aperture technologies aimed at enhancing near vision. The company offers the KAMRA inlay, designed to restore near vision for presbyopic patients while preserving distance vision. Additionally, AcuFocus develops the IC-8 IOL, a small aperture lens that facilitates a range of vision for patients with cataracts. The AcuTarget HD is another key product, serving as a diagnostic and surgical planning instrument for various vision correction procedures, including LASIK and cataract surgeries. AcuFocus markets its products through distribution partners across the Americas, Asia-Pacific, Europe, and the Middle East, addressing the needs of both physicians and patients in the vision care sector. Founded in 2001, AcuFocus continues to focus on innovative solutions for vision-related challenges.
Raptor Pharmaceuticals
Post in 2014
Raptor Pharmaceuticals Corp. is a development stage biotechnology company based in Novato, California, focused on discovering and developing innovative drug candidates for various serious conditions, including brain disorders, neurodegenerative diseases, genetic disorders, and cancers. The company is advancing several clinical-stage products, including DR Cysteamine, which is undergoing Phase IIb trials for nephropathic cystinosis and Phase IIa trials for non-alcoholic steatohepatitis, as well as Convivia for ALDH2 deficiency and additional candidates targeting Huntington's disease and migraine. Raptor is also engaged in preclinical development of therapies such as HepTide for hepatocellular carcinoma, WntTide for breast cancer, and NeuroTrans for neurodegenerative diseases. The company collaborates with academic institutions, including the University of California, San Diego, to enhance its research and clinical studies. Founded in 2005, Raptor Pharmaceuticals is dedicated to developing bio-pharmaceutical therapies aimed at treating debilitating and life-threatening diseases.
Invuity, Inc. is a medical technology company based in San Francisco, California, focused on developing and marketing advanced surgical devices in the United States and Asia. Utilizing its intelligent photonics technology platform, Invuity creates both single-use and reusable illuminated surgical devices that enhance visualization during surgical procedures. The company's product lineup includes various illuminated retractors and handheld illuminators designed for a range of specialties, such as breast, orthopedic, gynecological, and spinal surgeries. Notable offerings include the Eikon LT illuminated retractor system, Eiberg illuminated retractors, and the PhotonBlade and PhotonSaber series, which provide targeted illumination to improve surgical outcomes. Invuity sells its devices through direct sales representatives, independent agents, and directly to hospitals and surgeons, as well as to third-party medical device manufacturers. Previously known as Spotlight Surgical, Inc., Invuity was founded in 2004 and operates as a subsidiary of Stryker Corporation.
Nuron Biotech
Private Equity Round in 2014
Nuron Biotech Inc. develops specialty biologics and vaccines. Its product pipeline comprises central nervous system products, such as NU100, a recombinant human interferon beta-1b for the treatment of relapsing remitting multiple sclerosis; wound healing products, including NU200, a recombinant human epidermal growth factor product for healing diabetic foot ulcers and burns; and HibTITER, a conjugate vaccine. The company was founded in 2010 and is based in Exton, Pennsylvania.
Suneva Medical
Series B in 2014
Suneva Medical, Inc. is an aesthetics company based in San Diego, California, specializing in the development, manufacturing, and commercialization of innovative products for the dermatology, plastic, and cosmetic surgery markets. The company is best known for Bellafill, a unique dermal filler that is distinguished by its five-year safety and efficacy data and its approval for the correction of facial acne scars. In addition to Bellafill, Suneva Medical offers Puregraft, a fat grafting solution that enhances long-term graft retention, as well as a platform for processing platelet-rich plasma to optimize patient outcomes. The company is dedicated to delivering differentiated aesthetic products that provide high satisfaction for both patients and healthcare providers, thereby creating significant business opportunities for its partners. Suneva Medical was founded in 2008 and has an additional office in Santa Barbara, California.
Suneva Medical
Debt Financing in 2014
Suneva Medical, Inc. is an aesthetics company based in San Diego, California, specializing in the development, manufacturing, and commercialization of innovative products for the dermatology, plastic, and cosmetic surgery markets. The company is best known for Bellafill, a unique dermal filler that is distinguished by its five-year safety and efficacy data and its approval for the correction of facial acne scars. In addition to Bellafill, Suneva Medical offers Puregraft, a fat grafting solution that enhances long-term graft retention, as well as a platform for processing platelet-rich plasma to optimize patient outcomes. The company is dedicated to delivering differentiated aesthetic products that provide high satisfaction for both patients and healthcare providers, thereby creating significant business opportunities for its partners. Suneva Medical was founded in 2008 and has an additional office in Santa Barbara, California.
TearScience
Venture Round in 2013
TearScience, Inc. is a medical device company based in Morrisville, North Carolina, focused on the identification, diagnosis, and treatment of Meibomian Gland Dysfunction (MGD), which is the primary cause of evaporative dry eye affecting over 100 million people globally. The company has developed innovative devices such as the LipiFlow Activator, which delivers automated therapeutic energies to meibomian glands while safeguarding the eye's delicate structures, and LipiScan, an imaging system that allows eye care professionals to assess gland health. MGD is often under-recognized and contributes significantly to dry eye symptoms such as irritation, dryness, and visual disturbances. By providing a comprehensive in-office system, TearScience enables eye care professionals to effectively address the root causes of evaporative dry eye, ultimately improving patient outcomes. The company, originally known as Kolis Scientific, Inc., was rebranded in 2005 and is now a subsidiary of Johnson & Johnson Surgical Vision, Inc.
Nuron Biotech
Private Equity Round in 2012
Nuron Biotech Inc. develops specialty biologics and vaccines. Its product pipeline comprises central nervous system products, such as NU100, a recombinant human interferon beta-1b for the treatment of relapsing remitting multiple sclerosis; wound healing products, including NU200, a recombinant human epidermal growth factor product for healing diabetic foot ulcers and burns; and HibTITER, a conjugate vaccine. The company was founded in 2010 and is based in Exton, Pennsylvania.
AcuFocus
Venture Round in 2011
AcuFocus, Inc. is an ophthalmic medical device company based in Irvine, California, specializing in small aperture technologies aimed at enhancing near vision. The company offers the KAMRA inlay, designed to restore near vision for presbyopic patients while preserving distance vision. Additionally, AcuFocus develops the IC-8 IOL, a small aperture lens that facilitates a range of vision for patients with cataracts. The AcuTarget HD is another key product, serving as a diagnostic and surgical planning instrument for various vision correction procedures, including LASIK and cataract surgeries. AcuFocus markets its products through distribution partners across the Americas, Asia-Pacific, Europe, and the Middle East, addressing the needs of both physicians and patients in the vision care sector. Founded in 2001, AcuFocus continues to focus on innovative solutions for vision-related challenges.
Zogenix, Inc. is a pharmaceutical company focused on developing and commercializing innovative therapies for patients with rare diseases, particularly within the central nervous system. The company is headquartered in Emeryville, California, and was established in 2006. Its lead product candidate, Fintepla, is a low-dose fenfluramine currently undergoing Phase III clinical trials for the treatment of seizures related to Dravet syndrome and Lennox-Gastaut syndrome. Additionally, it is being investigated in Phase II trials for other rare epileptic conditions. Zogenix is also developing MT1621, a therapy aimed at treating inherited mitochondrial DNA depletion disorders. Furthermore, the company collaborates with Tevard Biosciences to explore gene therapies for Dravet syndrome and similar genetic epilepsies. By focusing on therapies that address significant unmet medical needs, Zogenix aims to enhance the quality of life for patients and their families.